Enanta Pharmaceuticals (NASDAQ:ENTA) Lowered to Sell Rating by StockNews.com

StockNews.com cut shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a sell rating in a research note released on Tuesday morning.

A number of other brokerages have also weighed in on ENTA. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday. JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday. Finally, Robert W. Baird dropped their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Price Performance

Enanta Pharmaceuticals stock opened at $7.50 on Tuesday. Enanta Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $17.80. The business has a 50 day simple moving average of $5.75 and a 200-day simple moving average of $9.51. The stock has a market capitalization of $159.98 million, a PE ratio of -1.37 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. As a group, equities research analysts anticipate that Enanta Pharmaceuticals will post -5.05 EPS for the current year.

Insider Buying and Selling at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly bought 45,000 shares of the stock in a transaction on Wednesday, February 12th. The shares were bought at an average price of $5.69 per share, with a total value of $256,050.00. Following the completion of the acquisition, the chief executive officer now owns 846,638 shares of the company’s stock, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 13.89% of the stock is owned by corporate insiders.

Institutional Trading of Enanta Pharmaceuticals

Several large investors have recently bought and sold shares of ENTA. China Universal Asset Management Co. Ltd. acquired a new stake in Enanta Pharmaceuticals in the fourth quarter valued at $26,000. US Bancorp DE boosted its stake in shares of Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 4,243 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Enanta Pharmaceuticals during the fourth quarter valued at $58,000. Wells Fargo & Company MN boosted its stake in shares of Enanta Pharmaceuticals by 69.6% during the fourth quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 6,518 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at $122,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.